Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04145141 · ClinicalTrials.gov registry record
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
A clinical trial of Hepatocellular Carcinoma and Liver Cancer, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 500
- Enrollment target
- 7
- Study locations
NCT04145141: Recruiting study of Hepatocellular Carcinoma and Liver Cancer, sponsored by National Cancer Institute (NCI).
NCT04145141 is a study of Hepatocellular Carcinoma and Liver Cancer that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 500 participants, above the 254-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (97% higher). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04145141, a study of Hepatocellular Carcinoma and Liver Cancer, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 7
- Study locations
Study Summary
Background: Primary Liver Cancer is the second most common cause of cancer-related death worldwide. It is the cancer with the fastest rising incidence and mortality in the United States. Researchers want to learn more about liver cancer to help them design better treatments. Objective: To better understand liver cancer. Eligibility: People ages 18 and older who have liver cancer and had or are planning to have immune therapy Design: Participants will be screened with a review of their medical records. They will be asked about their medical history and test results. Participants will come to the NIH Clinical Center. During this visit, their medical records, test results, imaging studies, and tissue samples (if available) will be gathered. Participants will learn the results of a test to see if they have any mutations known to be connected to cancer. They will learn if there are treatment options for them. Participants will give blood, urine, and stool samples or rectal swabs. Participants will not have follow-up visits just for this study. If they join another NIH research study and have visits for this other study, their medical records; test results; and blood, urine, and stool samples may be collected. This will occur about every 3 months. If they have a biopsy or surgery on another study or as part of treatment and there is leftover tissue, researchers would like to collect some of that tissue. Participants will be contacted every 6 months by phone or e-mail. They will be asked about their health. They will provide any medical records, test results, and imaging studies. Participants will be followed on this study for life.
Primary Outcome
Established biospecimen repository for genomic, genetic and epigenetic analysis to study the biology of PLC development and progression
Conditions Studied
Study Locations (7)
California
- University of California, San Diego (UCSD) - La Jolla
- University of California, San Francisco (UCSF) - San Francisco
District of Columbia
- Georgetown University - Washington D.C.
Maryland
- National Institutes of Health Clinical Center - Bethesda
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Thomas Jefferson University - Philadelphia
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2027-12-31 |
What NCT04145141 shows while recruiting
NCT04145141 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 254-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (97% higher).
The record links to 3 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT04145141 lists 7 locations in 6 states (California, District of Columbia, Maryland).
Frequently Asked Questions
What is clinical trial NCT04145141 about?
NCT04145141 is a clinical study titled "National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer". Background: Primary Liver Cancer is the second most common cause of cancer-related death worldwide. It is the cancer with the fastest rising incidence and mortality in the United States. Researchers want to learn more about liver cancer to help them design better treatments. Objective: To better ...
What is the current status of trial NCT04145141?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2021-07-28. Estimated completion is 2027-12-31.
What conditions does trial NCT04145141 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Liver Cancer, Cholangiocarcinoma.
Who is sponsoring clinical trial NCT04145141?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04145141 being conducted?
This trial has 7 study locations across California, District of Columbia, Maryland, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04145141's enrollment target sits among peer trials
500 26th of 145 higher than 119 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI